| Literature DB >> 29282592 |
Mónika Bálint1,2, Norbert Jeszenői3, István Horváth4, David van der Spoel5, Csaba Hetényi6.
Abstract
BACKGROUND: Targets with multiple (prerequisite or allosteric) binding sites have an increasing importance in drug design. Experimental determination of atomic resolution structures of ligands weakly bound to multiple binding sites is often challenging. Blind docking has been widely used for fast mapping of the entire target surface for multiple binding sites. Reliability of blind docking is limited by approximations of hydration models, simplified handling of molecular flexibility, and imperfect search algorithms.Entities:
Keywords: Complex; Dissociation; Flexibility; Interaction; Peptide; Pharmacodynamics; Pocket; Search; Structure; Water
Year: 2017 PMID: 29282592 PMCID: PMC5745209 DOI: 10.1186/s13321-017-0255-6
Source DB: PubMed Journal: J Cheminform ISSN: 1758-2946 Impact factor: 5.514
Fig. 1Wrap ‘n’ Shake flowchart featuring the main steps of the method. A quick overview is also presented in Additional file 1: Supporting Movie 1
Fig. 2Systematic calibration of εX and RX. a A section of the VXO(r, εX, RX) LJ potential function at r = 2 Å. Scenarios Sc1-Sc3 are shown with the magnitude of the RX values corresponding to a short range repulsion of VXO ≈ 1 kcal/mol (dashed lines) b VXO LJ potential functions of scenarios Sc1-Sc3. VOO of an oxygen atom pair is also shown for comparison. c An example of excluded atoms X (red, Cycle 1, Rank 2, System 9). Docked ligand conformation, is presented with sticks and the binding pocket is shown as surface. d Ligand of System 2 (dark blue sticks) bound to its target farnesyl pyrophosphate synthase (grey lines and surface) after Shaker (MDF step). Explicit water molecules surrounding the ligand within 7 Å are shown with sticks and light blue surface
Test systems
| # | PDB IDa | Target | Ligand | MWb |
|---|---|---|---|---|
| 1 | 3ptb | bovine β-trypsin | benzamidine | 120 |
| 2 | 3n3 l | farnesyl pyrophosphate synthase | (6-methoxy-1-benzofuran-3-yl) acetic acid (MS0) | 206 |
| 3a | 3hvc | mitogen-activated protein kinase | 4-[3-(4-fluorophenyl)-1 h-pyrazol-4-yl]pyridine (GG5) | 239 |
| 3b | 4f9w | mitogen-activated protein kinase | 4-[3-(4-fluorophenyl)-1 h-pyrazol-4-yl]pyridine (GG5) | 239 |
| 4 | 3cpa | carboxy-peptidase | GY | 256 |
| 5 | 1qcf | haematopoetic cell kinase (HCK) | 1-ter-butyl-3-p-tolyl-1 h-pyrazolo[3,4-d]pyrimidin- 4-ylamine (PP1) | 281 |
| 6 | 1h61 | pentaerythritol tetranitrate reductase | Prednisone® | 358 |
| 7 | 2bal | mitogen-activated protein kinase | [5-amino-1-(4- Fluorophenyl)-1H-Pyrazol-4- yl] [3-(piperidin-4-yloxy) phenyl]methanone | 380 |
| 8 | 1hvy | thymidylate synthase | Ralitrexed® | 459 |
| 9 | 3g5d | tyrosine-protein kinase Src | Dasatinib® | 488 |
| 10 | 1be9 | PDZ-domain | KQTSV | 544 |
aPDB ID of the holo X-ray structure
bMolecular weight of the ligand
Results for the test systems
| # | Na | CLSb | #Rankc | nd | SRe | |
|---|---|---|---|---|---|---|
| MDBSA | MDF | |||||
| 1a | 68 | 6 | 1 | 1 | 6 | 11 |
| 1bg | 74 | 5 | 1 | – | 4 | 19 |
| 1cg | 71 | 6 | 1 | – | 5 | 14 |
| 2 | 300 | 18 | 2 | 4 | 13 | 23 |
| 3a | 222 | 46 | 3 | 4 | 21 | 11 |
| 3b | 222 | 46 | 9 | 12 | 21 | 11 |
| 4 h | 155 | 12 | 1 | 1 | 8 | 19 |
| 5 | 143 | 25 | 2 | 1 | 12 | 12 |
| 6i | 116 | 26 | 1 | 2 | 12 | 10 |
| 7 | 123 | 26 | 4 | 4 | 12 | 10 |
| 8 | 106 | 25 | 1 | 1 | 10 | 11 |
| 9j | 92 | 23 | 2 | 1 | 10 | 9 |
| 10 | 49 | 11 | 2 | 1 | 4 | 12 |
aTotal count of ligand copies after Wrapper
bCount of ligands surviving the Shaker, after MDBSA
cRank serial number of the structure with the best RMSD value, after MDBSA and after MDF
dCount of cluster representatives (final solutions) Shaker
eShaker Rate
fTotal computational time required for MDB, MDBSA and MDF, as explained in Additional file 2: Table S12
gFor System 1, WnS was performed with different seeds for data reproduction purposes
hFinal clustering was done using van der Waals and Coulomb interactions due to interactions of zinc ion with the ligand
iWrapper process was done, using the LJ interaction as a scoring function, instead of AD4 (Additional file 2: Table S13)
jFinal clustering was done with 6 Å distance limit between clusters
Fig. 3Pilot molecular dynamics simulations. Benzamidine ligand (sticks) started the MD simulations from three positions at different distances (as indicated in the legend) from the native binding site on the trypsin target (grey cartoon). Arrows in a point from starting (t = 0 ns) to final (t = 1000 ns) ligand positions. Only two of the three 1000 ns-long simulations with the closest starting position succeeded in finding the reference binding pose (*) known from the crystallographic structure (3ptb). b Time-dependence of root mean squared deviation (RMSD) of the ligand measured from its reference pose
Fig. 4Wrapping tyrosine-protein kinase Src target into a mono-layer of ligand copies (System 5). a Unbound (ligand free) accessible surface area (ASA) of the target and the lowest Einter of the cluster representatives in consecutive wrapping cycles. Target-ligand interaction energy (Einter) increases with increasing number of cycles finding strong binding sites in the first few cycles, before the final, saturation region. ASA finally decreases below 1%. Structural images show the wrapping of the target (grey surface) with ligands (red). b The monolayer arrangement of the ligands (red sticks) wrapping the entire target surface (grey) after the final cycles. c A close-up of a section of the monolayer showing that the ligand copies are evenly arranged without overlap
Fig. 5Structural fits quantified as root mean squared deviation (RMSD) with values given in Å. Ligand conformations after Shaker (grey) compared to the crystallographic references (red sticks). System# is bold
Fig. 6Haematopoetic cell kinase (HCK, System 5) with ligand copies remaining after Shaker. Ligand copies are colored by the calculated target-ligand interaction energy E, and the #Rank assigned. The previously reported pockets 1(ATP), 2(A-loop), 3(PIF site), 4(G-loop) and 5(MYR) are numbered by their increasing ELJ
Fig. 7During Shaker, conformational changes of the pentapeptide KQTSV are observed, while remains bound to its pocket on the PDZ domain (System 10). Red sticks represent the native ligand conformation from PDB (1be9). Teal sticks represent ligand conformations at different Shaker stages starting with the conformation right after Wrapper (1), and continuing with conformation after MDBSA (2), and after MDF (3). The changes of target-ligand interaction energy (ELJ) and the RMSD during the MD stages in the Shaker protocol are plotted below the structural snapshots. See also Additional file 3: Supporting Movie 2 for further details of conformational changes